Lv1
80 积分 2024-03-21 加入
Beyond resmetirom approval for NAFLD: what has to be done?
1个月前
已完结
Health-Related quality of life (HRQL) assessments in a 52-Week, Double-Blind, randomized, Placebo-Controlled phase 3 study of resmetirom (MGL-3196) in patients with metabolic dysfunction associated steatohepatitis (MASH) and fibrosis
1个月前
已完结
NAFLD and thyroid function: pathophysiological and therapeutic considerations
6个月前
已完结
Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-β agonist
7个月前
已完结
皖公网安备34019202002308
